| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$107.3M | ROE | −28.22% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines for patients with central nervous system disorders. Its lead candidate is RAP-219, designed to inhibit TARPy8-containing AMPARs for treating focal epilepsy and other CNS disorders including peripheral neuropathic pain and bipolar disorder. The company also develops nicotinic acetylcholine receptor programs targeting chronic pain, migraine, and hearing and vestibular disorders.
| Market Cap | $2.01B | Trading Days | 532 |
| 52W High | 44.28 |
| 52W Low | 13.62 |
| % Off High | −5.24% |
| YTD | 38.30% | 1Y | 150.66% |
| Since incept. (ann.) | 38.85% |
| Ann. Volatility (1Y) | 136.51% | Ann. Volatility (3Y) | 122.29% |
| Sharpe (1Y) | 1.14 | Sharpe (3Y) | 0.76 |
| Max Drawdown (1Y) | −28.82% | Max Drawdown (3Y) | −75.54% |
| Beta (3Y, vs SPY) | 0.94 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SLS | SELLAS Life Sciences Group, Inc. | $2.02B | — |
| URGN | UroGen Pharma Ltd. | $2.02B | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.03B | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.03B | — |
| SION | Sionna Therapeutics, Inc. | $2.05B | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.96B | 7.4 |
| ZBIO | Zenas BioPharma, Inc. | $2.07B | — |
| PGEN | PRECIGEN, INC. | $1.93B | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.08B | 13.3 |
| ANIP | ANI PHARMACEUTICALS INC | $1.91B | 23.6 |
| OCUL | OCULAR THERAPEUTIX, INC | $1.89B |
| — |
| IMUX | IMMUNIC, INC. | $2.15B | — |
